Finance

Lists
069620:KRX
Daewoong Pharma
â‚©126,800.00
-0.16%
(-200.00) 1D
Sep 1, 3:30:10 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 069620...
Open
â‚©127,200
High
â‚©128,500
Low
â‚©124,900
Mkt. cap
1.47T
Avg. vol.
31.25K
Volume
18.63K
Dividend
0.47%
Quarterly dividend
â‚©150
Ex-dividend date
Dec 27, 2023
P/E ratio
7.46
52-wk high
â‚©199,400
52-wk low
â‚©105,000
EPS
â‚©16,988
Shares outstanding
11.59M
No. of employees
2K
Open
â‚©127,200
High
â‚©128,500
Low
â‚©124,900
Mkt. cap
1.47T
Avg. vol.
31.25K
Volume
18.63K
Dividend
0.47%
Quarterly dividend
â‚©150
Ex-dividend date
Dec 27, 2023
P/E ratio
7.46
52-wk high
â‚©199,400
52-wk low
â‚©105,000
EPS
â‚©16,988
Shares outstanding
11.59M
No. of employees
2K
Profile
Daewoong Pharmaceutical Co., Ltd. is a pharmaceutical company headquartered in Seoul, South Korea. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products, including prescription and over-the-counter healthcare products. Wikipedia
About Daewoong Pharma
CEOChang-jae Lee | Seongsoo Park
Employees1.75K
Founded1945
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
411.83B
397.12B
377.80B
448.46B
Cost of goods sold
198.11B
185.96B
196.61B
199.39B
Cost of revenue
198.11B
185.96B
196.61B
199.39B
Research and development expenses
8.31B
139.98B
16.11B
14.81B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
144.21B
23.12B
136.65B
154.92B
Operating expense
156.83B
169.10B
158.98B
181.01B
Total operating expenses
354.94B
355.06B
355.59B
380.40B
Operating income
56.89B
42.06B
22.21B
68.07B
Other non operating income
-1.16B
2.77B
1.52B
-36.53B
EBT including unusual items
54.73B
68.97B
33.97B
21.89B
EBT excluding unusual items
54.73B
88.02B
11.82B
21.89B
Income tax expense
7.42B
-16.73B
8.46B
1.98B
Effective tax rate
13.56%
-24.26%
24.89%
9.02%
Other operating expenses
1.17B
1.17B
1.88B
1.61B
Net income
46.37B
89.84B
25.90B
33.37B
Net profit margin
11.26%
22.62%
6.86%
7.44%
Earnings per share
-
-
-
-
Interest and investment income
-
1.12B
1.74B
-
Interest expense
-
-3.53B
-8.00B
-
Net interest expenses
-
-2.41B
-6.26B
-
Depreciation and amortization charges
1.77B
1.43B
1.15B
7.94B
EBITDA
69.45B
56.04B
38.38B
92.95B
Gain or loss from assets sale
-12.80M
-52.31B
35.01M
-7.54M
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps